Muthu shares insights on the contrasting dynamics of healthcare and technology investments, emphasizing a preference for public markets in life sciences due to capital efficiency concerns. He discusses the strategy of long-short investing in a fertile shorting market, highlighting the importance of clear catalysts in stock performance. While acknowledging a mismatch with public market benchmarks, Muthu remains confident that their private market exposure will outperform over market cycles.
